Inhalation of silica in mining, sandblasting and quarrying occupations results in serious, potentially life threatening, pulmonary inflammatory and fibrotic pathologies including acute and chronic (nodular pulmonary fibrosis) silicosis. Thus the first objective of this proposal is to determine the mechanisms underlying silica-induced pulmonary inflammation and fibrosis, particularly the role of the cytokine transforming growth factor beta 1(TGfb1). TGFb is strongly implicated in pulmonary fibrosis induced by silica and other agents. The second objective is to develop novel gene-based therapeutic strategies for treatment of these fibrotic pathologies. The hypothesis will be tested that activated TGFb is a key mediator of crystalline silica-mediated fibrosis, and if inhibited a fibrotic outcome can be prevented. Two different anti-TGFb strategies will be utilized. The first will involve adenoviral vector mediated overexpression of the core protein of the proteoglycan decorin in mouse lung. Decorin is a physiological inhibitor of active TGFb. The second strategy will exploit the inhibitory nature of the pre-proportion of the TGFb molecule itself, termed the LAP. Transgenic mice over-expressing LAP under control of the lung specific SP- C promoter will be used, and should produce prolonged inhibition of active TGFb. Unlike crystalline silica, amorphous silica induces inflammation, but not fibrogenesis. It is hypothesized that this is related to failure of amorphous silica to upregulate active TGFb. The concept will be tested that over-expression of low levels of active TGFb, in the context of ongoing amorphous silica-induced injury and inflammation, will drive silica-mediated inflammation to fibrogenesis. Assessment will also be made of the ability this inflammatory milieu itself to activate latent TGFb. Finally, to further address the mechanisms of inflammation and fibrogenesis induced by different silicas, their potential to activate fibroblasts in vitro will be examined. The PI of this project has just been recruited as faculty to the Depts. of Medicine and Environmental Medicine. She is committed to an academic career, and will spend 80% of her time in research studies. She has had previous training in inflammation, fibrogenesis and gene transfer, and now plans to expand her studies to investigate environmental and occupational lung disease. To achieve this she wishes to obtain additional training in environmental toxicology, and the role of the immune system in fibroblast activation. The environment in Rochester has a critical mass of international experts in these areas, whose interests are aligned with those of the PI. They will collaborate with the PI, and form her advisory committee. In conjunction with a formal education program me this should allow her to successfully develop as an independent investigator, while yielding new insights into the pathogenesis and treatment of fibrotic pathologies.

Agency
National Institute of Health (NIH)
Institute
National Heart, Lung, and Blood Institute (NHLBI)
Type
Clinical Investigator Award (CIA) (K08)
Project #
5K08HL004492-02
Application #
6536668
Study Section
Special Emphasis Panel (ZHL1-CSR-K (O1))
Program Officer
Colombini-Hatch, Sandra
Project Start
2001-04-01
Project End
2006-03-31
Budget Start
2002-04-01
Budget End
2003-03-31
Support Year
2
Fiscal Year
2002
Total Cost
$127,724
Indirect Cost
Name
University of Rochester
Department
Internal Medicine/Medicine
Type
Schools of Dentistry
DUNS #
208469486
City
Rochester
State
NY
Country
United States
Zip Code
14627
Rico de Souza, Angela; Zago, Michela; Pollock, Stephen J et al. (2011) Genetic ablation of the aryl hydrocarbon receptor causes cigarette smoke-induced mitochondrial dysfunction and apoptosis. J Biol Chem 286:43214-28
Sime, Patricia J (2008) The antifibrogenic potential of PPARgamma ligands in pulmonary fibrosis. J Investig Med 56:534-8
Thatcher, Thomas H; Maggirwar, Sanjay B; Baglole, Carolyn J et al. (2007) Aryl hydrocarbon receptor-deficient mice develop heightened inflammatory responses to cigarette smoke and endotoxin associated with rapid loss of the nuclear factor-kappaB component RelB. Am J Pathol 170:855-64
Baglole, Carolyn J; Bushinsky, Seth M; Garcia, Tatiana M et al. (2006) Differential induction of apoptosis by cigarette smoke extract in primary human lung fibroblast strains: implications for emphysema. Am J Physiol Lung Cell Mol Physiol 291:L19-29
Viscardi, Rose M; Atamas, Sergei P; Luzina, Irina G et al. (2006) Antenatal Ureaplasma urealyticum respiratory tract infection stimulates proinflammatory, profibrotic responses in the preterm baboon lung. Pediatr Res 60:141-6
Lakatos, Heather F; Burgess, Heather A; Thatcher, Thomas H et al. (2006) Oropharyngeal aspiration of a silica suspension produces a superior model of silicosis in the mouse when compared to intratracheal instillation. Exp Lung Res 32:181-99
Baglole, Carolyn J; Ray, Denise M; Bernstein, Steven H et al. (2006) More than structural cells, fibroblasts create and orchestrate the tumor microenvironment. Immunol Invest 35:297-325
Thatcher, Thomas H; Sime, Patricia J; Barth, Richard K (2005) Sensitivity to bleomycin-induced lung injury is not moderated by an antigen-limited T-cell repertoire. Exp Lung Res 31:685-700
Thatcher, T H; McHugh, N A; Egan, R W et al. (2005) Role of CXCR2 in cigarette smoke-induced lung inflammation. Am J Physiol Lung Cell Mol Physiol 289:L322-8
Burgess, Heather A; Daugherty, Louis Eugene; Thatcher, Thomas H et al. (2005) PPARgamma agonists inhibit TGF-beta induced pulmonary myofibroblast differentiation and collagen production: implications for therapy of lung fibrosis. Am J Physiol Lung Cell Mol Physiol 288:L1146-53

Showing the most recent 10 out of 18 publications